ViaLase, Inc

ViaLase is a venture-backed medical technology company focused on revolutionizing glaucoma treatment with the ViaLuxe™ Laser System. This noninvasive system utilizes femtosecond laser precision and micron-accurate image guidance to create customized drainage channels within the eye, aiming to reduce intraocular pressure without invasive surgery. The company boasts a team with extensive experience in developing and commercializing femtosecond laser technology for ophthalmic procedures, bringing this expertise to the glaucoma market.

Currently in the clinical stage, ViaLase is actively conducting trials and collaborating with healthcare providers to advance the development of their groundbreaking technology. Their goal is to provide a safe and effective treatment option for the millions of people living with glaucoma, one of the leading causes of irreversible blindness worldwide. ViaLase aims to disrupt the conventional glaucoma treatment paradigm by offering a minimally disruptive, non-surgical alternative to current options.

ViaLase, Inc. is a clinical stage medical technology company dedicated to revolutionizing glaucoma treatment with the development of a truly noninvasive, image-guided femtosecond laser treatment. Their mission is to disrupt the conventional glaucoma treatment paradigm and enhance patient care by providing a safe and effective alternative to traditional invasive procedures, thereby improving the lives of millions affected by this leading cause of irreversible blindness worldwide.

ViaLase fosters a culture of innovation, collaboration, and a commitment to patient care. They are driven by a shared passion for redefining glaucoma treatment and believe in working closely with healthcare providers, payers, societies, and patients to inform their product development and commercial activities. The company values a diverse and inclusive work environment where individuals with vast experience in ophthalmology can contribute their expertise towards achieving their ambitious goal of bringing revolutionary, noninvasive glaucoma treatment to patients worldwide.